Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill tame the obesity epidemic?

NCT ID NCT07743463

Disease control Sponsor: Ascletis Pharma (China) Co., Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Sep 17, 2026 · Updated 4 times

Summary

This Phase 3 trial is testing an experimental once-daily oral medication called ASC30 in adults with obesity or overweight who also have weight-related health conditions like high blood pressure or sleep apnea. The study aims to see if ASC30 can lead to significant weight loss over 72 weeks compared to a placebo. It will also measure changes in waist size, blood pressure, and other health markers. The trial is double-blind and placebo-controlled, meaning neither participants nor researchers will know who receives the actual drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ASC30, an experimental once-daily oral medication
What this could lead to
If successful, ASC30 could offer a convenient daily pill for chronic weight management, potentially aiding in weight loss and improving related health issues like blood pressure and cholesterol.
What could go wrong
This is a large, late-stage trial, but success is not guaranteed. The drug may not produce significant weight loss or may cause side effects. Long-term safety and effectiveness are still under investigation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 3,003 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening. 2. Have a BMI ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening: * Hypertension * Dyslipidemia * Obstructive sleep apnea * Cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure). 3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: 1. Have any prior diagnosis of diabetes mellitus (T1DM or T2DM), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma. Participants with a history of gestational diabetes are eligible to participate in this trial. 2. Have a self-reported change in body weight \>5 kg (11 pounds) within 3 months prior to screening. 3. Have an estimated glomerular filtration rate (eGFR) \< 15 mL/min/1.73 m2, as determined by the laboratory at screening. 4. Have a history of acute or chronic pancreatitis any time prior to screening. 5. Have known allergies or intolerance to other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs. 6. Participants with a personal or family (first-degree relative) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia (MEN) syndrome type 2. 7. Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study at the investigator's discretion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic weight management are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic weight management Obesity Obesity or overweight with weight-related comorbidities Overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    122 sites in 7 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Birmingham, Alabama, 35211-1320, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Huntsville, Alabama, 35802, United States

  • AURORA-1 Clinical Site

    RECRUITING

    Phoenix, Arizona, 85020, United States

    Contact Email: •••••@•••••

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Tucson, Arizona, 85741, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Little Rock, Arkansas, 72204, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Banning, California, 92220-3082, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Chula Vista, California, 91910, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Covina, California, 91723-1905, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Gardena, California, 90247-3583, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    La Mesa, California, 91942, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Los Angeles, California, 91405, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Tarzana, California, 91356-3508, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Tustin, California, 92780-7074, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Washington D.C., District of Columbia, 20016, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Boca Raton, Florida, 33434, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Daytona Beach, Florida, 32114, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Jacksonville, Florida, 32205-4785, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Leesburg, Florida, 34748-5077, United States

  • AURORA-1 Clinical Site

    RECRUITING

    Melbourne, Florida, 32934-8172, United States

    Contact Email: •••••@•••••

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    South Miami, Florida, 33143, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Tampa, Florida, 33613-1244, United States

  • AURORA-1 Clinical Site

    RECRUITING

    The Villages, Florida, 32162, United States

    Contact Email: •••••@•••••

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Winter Park, Florida, 32789-4681, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Canton, Georgia, 30115, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Decatur, Georgia, 30030-3440, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Union City, Georgia, 30291-2085, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Boise, Idaho, 83704, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Schaumburg, Illinois, 60173, United States

  • AURORA-1 Clinical Site

    RECRUITING

    Evansville, Indiana, 47714-7513, United States

    Contact Email: •••••@•••••

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Indianapolis, Indiana, 46254, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Valparaiso, Indiana, 46383, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Kansas City, Kansas, 66112, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Baton Rouge, Louisiana, 70809-3416, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Bowie, Maryland, 20715, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Rockville, Maryland, 20854-2931, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Gulfport, Mississippi, 39503-2637, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Jackson, Mississippi, 39206, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Olive Branch, Mississippi, 38654-3514, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    St Louis, Missouri, 63141, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Las Vegas, Nevada, 89113, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    New Windsor, New York, 12553-7754, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Charlotte, North Carolina, 28262, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Greenville, North Carolina, 27834-5051, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Morehead City, North Carolina, 28557, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Raleigh, North Carolina, 27610, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Cincinnati, Ohio, 45246, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44122-4330, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Columbus, Ohio, 43212-3122, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Dayton, Ohio, 45414, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Eugene, Oregon, 97404-3233, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Bluffton, South Carolina, 29910, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Clemson, South Carolina, 29634, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Columbia, South Carolina, 29204, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Gaffney, South Carolina, 29340-4737, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Memphis, Tennessee, 38119-4823, United States

  • AURORA-1 Clinical Site

    RECRUITING

    Austin, Texas, 78744-1645, United States

    Contact Email: •••••@•••••

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Brownsville, Texas, 78520, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    DeSoto, Texas, 75115-2043, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Frisco, Texas, 75033-4133, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Mesquite, Texas, 75149, United States

  • AURORA-1 Clinical Site

    RECRUITING

    San Antonio, Texas, 78229-3272, United States

    Contact Email: •••••@•••••

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    San Antonio, Texas, 78229-3539, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Sugar Land, Texas, 77478, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Tomball, Texas, 77375, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Weslaco, Texas, 78596-7288, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Wichita Falls, Texas, 76301, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Salt Lake City, Utah, 84124-3543, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Hampton, Virginia, 23666, United States

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Burlington, L7R 1E2, Canada

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Pardubice, 530 02, Czechia

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Prague, 120 00, Czechia

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Prague, 150 00, Czechia

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Uherské Hradiště, 686 01, Czechia

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Berlin, 10629, Germany

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Berlin, 10787, Germany

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Essen, 45355, Germany

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Hanover, 30159, Germany

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Leipzig, 04107, Germany

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Athens, 106 76, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Athens, 115 27, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Athens, 115 28, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Larissa, 411 10, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Marousi, 151 23, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Palaió Fáliro, 175 62, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Pylaia, 570 01, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Thessaloniki, 546 36, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Thessaloniki, 546 42, Greece

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Biała Podlaska, 21-500, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Bydgoszcz, 85-092, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Częstochowa, 42-202, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Gdansk, 80-382, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Gdynia, 81-384, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Gdynia, 81-537, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Katowice, 40-040, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Krakow, 31-261, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Krakow, 31-501, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Lodz, 90-127, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Lodz, 91-363, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Lublin, 20-011, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Lublin, 20-362, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Poznan, 60-324, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Poznan, 60-702, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Puławy, 24-100, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Siedlce, 08-110, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Staszów, 28-200, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Torun, 87-100, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Warsaw, 00-215, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Warsaw, 00-710, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Warsaw, 01-696, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Warsaw, 02-672, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Warsaw, 03-291, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Wroclaw, 50-381, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Wroclaw, 53-673, Poland

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Bellshill, ML4 3NJ, United Kingdom

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Cardiff, CF15 9SS, United Kingdom

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Edgbaston, B16 8QQ, United Kingdom

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    London, E1 1AG, United Kingdom

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Manchester, M11 1AA, United Kingdom

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Manchester, M156SE, United Kingdom

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Stoke-on-Trent, ST1 5SJ, United Kingdom

  • AURORA-1 Clinical Site

    NOT_YET_RECRUITING

    Warrington, WA1 3TZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.